AllSight
Companies · TYRA · Pharmaceutical Preparations

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Tyra Biosciences, Inc. (TYRA) stock — financials & valuation

Key numbers for Tyra Biosciences, Inc. (TYRA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 37/100 — a percentile rank of Tyra Biosciences, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$1.5B
EV / EBITDA-8.9×
Return on equity-41.9%
ROIC-57.3%
Debt / equity0.0×
Dividend yield0.0%

Is Tyra Biosciences, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Tyra Biosciences, Inc.’s own financial statements and shown as context, never as advice.

Sep 14, 2026$400M equity raise
Tyra Biosciences prices $400M equity raise as pivotal trial work accelerates
Sep 9, 2026Below the bar
Tyra’s SURF302 shows clean safety, but efficacy misses the 70% CR bar
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact